Who are Vecuronium + Atracurium's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Neuromuscular Blocking Agents, NMBA - cisatracurium, Rocuronium dosing, Rocuronium or Vecuronium, Deep neuromuscular block, Rocuronium + sugammadex.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vecuronium-atracurium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Vecuronium + Atracurium — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vecuronium + Atracurium (Vecuronium + Atracurium) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuromuscular blocking agent (non-depolarizing). Area: Anesthesiology.

marketed Neuromuscular blocking agent (non-depolarizing) Nicotinic acetylcholine receptor at the neuromuscular junction Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Vecuronium + Atracurium (Vecuronium + Atracurium) — Sir Ganga Ram Hospital. Vecuronium and atracurium are neuromuscular blocking agents that competitively inhibit acetylcholine at the neuromuscular junction, causing muscle paralysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Vecuronium + Atracurium TARGET	Vecuronium + Atracurium	Sir Ganga Ram Hospital	marketed	Neuromuscular blocking agent (non-depolarizing)	Nicotinic acetylcholine receptor at the neuromuscular junction
Neuromuscular Blocking Agents	Neuromuscular Blocking Agents	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	marketed	Neuromuscular blocking agent	Nicotinic acetylcholine receptor at the neuromuscular junction
NMBA - cisatracurium	NMBA - cisatracurium	CHU de Reims	marketed	Non-depolarizing neuromuscular blocking agent (NMBA)	Nicotinic acetylcholine receptor at the neuromuscular junction
Rocuronium dosing	Rocuronium dosing	Clare Hayes-Bradley	marketed	Neuromuscular blocking agent (non-depolarizing)	Nicotinic acetylcholine receptor at the neuromuscular junction
Rocuronium or Vecuronium	Rocuronium or Vecuronium	Merck Sharp & Dohme LLC	marketed	Neuromuscular blocking agent (non-depolarizing)	Nicotinic acetylcholine receptor at the neuromuscular junction
Deep neuromuscular block	Deep neuromuscular block	University of Medicine and Pharmacy at Ho Chi Minh City	marketed		Nicotinic acetylcholine receptor at the neuromuscular junction
Rocuronium + sugammadex	Rocuronium + sugammadex	Brno University Hospital	marketed	Neuromuscular blocking agent (rocuronium) + selective relaxant binding agent (sugammadex)	Nicotinic acetylcholine receptor at the neuromuscular junction (rocuronium); rocuronium molecule itself (sugammadex)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuromuscular blocking agent (non-depolarizing) class)

Clare Hayes-Bradley · 1 drug in this class
Diskapi Yildirim Beyazit Education and Research Hospital · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Sir Ganga Ram Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vecuronium + Atracurium — Competitive Intelligence Brief. https://druglandscape.com/ci/vecuronium-atracurium. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab